Jounce Therapeutics, Inc. (JNCE): Price and Financial Metrics

Jounce Therapeutics, Inc. (JNCE)

Today's Latest Price: $6.82 USD

0.00 (0.00%)

Updated Nov 24 4:00pm

Add JNCE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

JNCE Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for Jounce Therapeutics Inc; that's greater than it is for only 12.24% of US stocks.
  • Over the past twelve months, JNCE has reported earnings growth of -175.29%, putting it ahead of just 11.2% of US stocks in our set.
  • Revenue growth over the past 12 months for Jounce Therapeutics Inc comes in at 89.43%, a number that bests 94.05% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Jounce Therapeutics Inc are DTIL, MGEN, GLYC, LPTX, and FULC.
  • Visit JNCE's SEC page to see the company's official filings. To visit the company's web site, go to

JNCE Stock Price Chart Interactive Chart >

Price chart for JNCE

JNCE Price/Volume Stats

Current price $6.82 52-week high $11.72
Prev. close $6.82 52-week low $2.85
Day low $6.70 Volume 187,000
Day high $7.07 Avg. volume 594,017
50-day MA $8.46 Dividend yield N/A
200-day MA $6.12 Market Cap 271.78M

Jounce Therapeutics, Inc. (JNCE) Company Bio

Jounce Therapeutics, Inc. focuses on developing cancer immunotherapy treatments that enable the immune system to attack tumors. The company in 2012 and is based in Cambridge, Massachusetts.

JNCE Latest News Stream

Event/Time News Detail
Loading, please wait...

JNCE Latest Social Stream

Loading social stream, please wait...

View Full JNCE Social Stream

Latest JNCE News From Around the Web

Below are the latest news stories about Jounce Therapeutics Inc that investors may wish to consider to help them evaluate JNCE as an investment opportunity.

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

Jounce Therapeutics (JNCE) Investor Presentation - Slideshow

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT …

Benzinga | August 7, 2020

Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2020 financial results and provide a corporate update before market open on Friday, August 7, 2020. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3898328. The live webcast can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at The webcast wi...

Yahoo | July 31, 2020

Should You Avoid Jounce Therapeutics, Inc. (JNCE)?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 6, 2020

Read More 'JNCE' Stories Here

JNCE Price Returns

1-mo -28.13%
3-mo 40.33%
6-mo 26.06%
1-year 43.28%
3-year -55.51%
5-year N/A
YTD -21.88%
2019 159.05%
2018 -73.57%
2017 N/A
2016 N/A
2015 N/A

Continue Researching JNCE

Want to see what other sources are saying about Jounce Therapeutics Inc's financials and stock price? Try the links below:

Jounce Therapeutics Inc (JNCE) Stock Price | Nasdaq
Jounce Therapeutics Inc (JNCE) Stock Quote, History and News - Yahoo Finance
Jounce Therapeutics Inc (JNCE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8648 seconds.